MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:41Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Aminoglycosides]]
			[[Category:Antibacterials]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #298

2026-05-23T04:08:53Z

parser-claude batch MedTemplate pre-fill, Top 300 #298

New page

{{MedTemplate
| generic = Tobramycin
| brand = Tobrex (ophthalmic), Tobi, Tobi Podhaler, Bethkis (inhaled, cystic fibrosis), generic IV
| structure =
| classes = [[:Category:Aminoglycosides|Aminoglycoside antibiotic]], [[:Category:Antibacterials|Antibacterial]]
| uses = <vote slug="gram-negative-sepsis-use">Gram-negative sepsis (with β-lactam, IV)</vote>, <vote slug="cf-pseudomonas-use">Cystic fibrosis Pseudomonas suppression (inhaled)</vote>, <vote slug="bacterial-conjunctivitis-use">Bacterial conjunctivitis (topical ophthalmic)</vote>, <vote slug="bacterial-keratitis-use">Bacterial keratitis (topical ophthalmic)</vote>
| starting_dose = IV: traditional 1-1.7 mg/kg q8h or extended-interval 5-7 mg/kg q24h with target-trough monitoring; inhaled CF 300 mg BID × 28 days on / 28 days off; ophthalmic 1-2 drops in affected eye(s) q4h
| preparations = IV 10 mg/mL, 40 mg/mL; inhaled 300 mg/5 mL solution (Tobi, Bethkis); Podhaler dry powder; 0.3% ophthalmic solution and ointment
| fda_max = IV: monitored by levels (trough <1 mg/L for extended-interval; <2 mg/L for traditional)
| pill_id =
| routes = IV, IM, inhaled, ophthalmic, intravitreal
| onset = Hours (systemic); minutes (ophthalmic)
| duration = 6-12 hours systemic
| halflife = 2-3 hours (normal renal function); markedly prolonged in renal impairment<ref name="tobi-label">FDA Prescribing Information, Tobi (tobramycin) inhalation solution, Novartis, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/050753s016lbl.pdf</ref>
| bioavailability = IV/IM ~100%; inhaled: minimal systemic; oral: negligible (not used orally for systemic infection)<ref name="tobi-label" />
| pregnancy = Aminoglycoside-class ototoxicity in fetal cochlea is documented; use only when alternatives have failed.{{citation needed}}
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="tobramycin-mech-claim">Tobramycin binds the 30S bacterial ribosomal subunit at the A site, causing translational misreading and premature termination; bactericidal activity is concentration-dependent, which is the pharmacodynamic basis of extended-interval (once-daily) IV dosing in critically ill patients.</vote> Class concerns: nephrotoxicity (acute tubular necrosis, usually reversible) and ototoxicity (cochlear and vestibular, often irreversible). Therapeutic drug monitoring (peaks for efficacy in traditional regimens, troughs for toxicity in both) is standard. Inhaled use bypasses systemic toxicity for CF Pseudomonas suppression<ref name="tobi-label" />.
}}

== References ==
<references />

Tobramycin - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #298